Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes

Atherosclerosis

Volumn 205, Issue 1, 2009, Pages 221-226

  Papathanassiou, Katerina ^a   Naka, Katerina K ^a   Kazakos, Nikolaos ^a,b   Kanioglou, Chryssanthi ^a   Makriyiannis, Demetrios ^c   Pappas, Konstantinos ^a   Katsouras, Christos S ^a   Liveris, Konstantinos ^a,d   Kolettis, Theofilos ^a   Tsatsoulis, Agathocles ^a   Michalis, Lampros K ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b Arta General Hospital   (Greece)

^c G HATZIKOSTA GENERAL HOSPITAL   (Greece)

^d Zakynthos General Hospital   (Greece)

Author keywords

Atherosclerosis; Diabetes; Endothelial function; Glimepiride; Insulin resistance; Pioglitazone

Indexed keywords

ANGIOTENSIN II ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLIMEPIRIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; PIOGLITAZONE;

ADULT; ARTERY DILATATION; ARTICLE; BLOOD VESSEL FUNCTION; BRACHIAL ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LEG EDEMA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VASCULAR ENDOTHELIUM; WAIST CIRCUMFERENCE;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; METFORMIN; MIDDLE AGED; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 67349136326     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.11.027     Document Type: Article

References (29)

1. Engelgau M.M., Geiss L.S., Saaddine J.B., et al. The evolving diabetes burden in the United States. Ann Intern Med 140 (2004) 945-950
2. Henderson A.H. Endothelial dysfunction: a reversible clinical measure of atherogenic susceptibility and cardiovascular inefficiency. Int J Cardiol 62 (1997) S43-S48
3. Calles-Escandon J., and Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 22 (2001) 36-52
4. Fonseca V.A. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus. Am J Med 120 (2007) S18-S25
5. Nissen S.E., Nicholls S.J., Wolski K., et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299 (2008) 1561-1573
6. Horio T., Suzuki M., Takamisawa I., et al. Pioglitazone-induced insulin sensitization improves vascular endothelial function in nondiabetic patients with essential hypertension. Am J Hypertens 18 (2005) 1626-1630
7. Mazzone T., Meyer P.M., Feinstein S.B., et al. Effect of pioglitazone compared with glimepiride on carorid intima-media thickness in type 2 diabetes. JAMA 296 (2006) 2572-2581
8. Lincoff A.M., Wolski K., Nicholls S.J., and Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. JAMA 298 (2007) 1180-1188
9. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PRO-active Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomized controlled trial. Lancet 366 (2005) 1279-1289
10. UK Prospective Diabetes Study Group. Intensive blood-glucose with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
11. Legro R.S., Finegood D., and Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 83 (1998) 2694-2698
12. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
13. Kravariti M., Naka K.K., Kalantaridou S.N., et al. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 90 (2005) 5088-5095
14. Corretti M.C., Anderson T.J., Benjamin E.J., et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39 (2002) 257-265
15. Gokce N., Keaney Jr. J.F., Hunter L.M., et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 41 (2003) 1769-1775
16. Shimbo D., Grahame-Clarke C., Miyake Y., et al. The association between endothelial dysfunction and cardiovascular outcomes in a population-based multi-ethnic cohort. Atherosclerosis 192 (2007) 197-203
17. Modena M.G., Bonetti L., Coppi F., Bursi F., and Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol 40 (2002) 505-510
18. Martens F.M., Visseren F.L., de Koning E.J., and Rabelink T.J. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol 46 (2005) 773-778
19. Wajcberg E., Sriwijitkamol A., Musi N., DeFronzo R.A., and Cersosimo E. Relationship between vascular reactivity and lipids in Mexican-Americans with type 2 diabetes treated with pioglitazone. J Clin Endocrinol Metab 92 (2007) 1256-1262
20. Fernandez M., Triplitt C., Wajcberg E., et al. Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms. Diabetes Care 31 (2008) 121-127
21. Sourij H., Zweiker R., and Wascher T. Effects of pioglitazone on endothelial function, insulin sensitivity and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes. Diabetes Care 29 (2006) 1039-1045
22. Campia U., Matuskey L.A., and Panza J.A. Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation 113 (2006) 867-875
23. Natali A., Baldeweg S., Taschi E., et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 27 (2004) 1349-1357
24. Mittermayer F., Schaller G., Pleiner J., et al. Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction. J Clin Endocrinol Metab 92 (2007) 2574-2580
25. Pfützner A., Marx N., Lübben G., et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 45 (2005) 1925-1931
26. Marx N., Duez H., Fruchart J.C., and Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 94 (2004) 1168-1178
27. Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P, on behalf of the QUARTET Study Group. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med 2005; 22:399-405.
28. Singh S., Loke Y.K., and Furberg C.D. Long-term risk of cardiovascular events with rosiglitazone. JAMA 298 (2007) 1189-1195
29. Pistrosch F., Passauer J., Fischer S., et al. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 27 (2004) 484-490